News & Analysis

Johnson & Johnson Q4 results are in

26 January 2022 By Klavs Valters


Johnson & Johnson (JNJ) reported its Q4 earnings before the opening bell on Wall Street on Tuesday. Let’s take a closer look at how the pharmaceutical giant performed in the previous quarter.

The company reported total revenue of $24.804 billion in Q4 (up by 10.4% from the same period in 2020), below analyst forecast of $25.276 billion.

Earnings per share at $2.13 a share in the previous quarter (up by 14.5%, pretty much in line with analyst forecast of $2.12 a share.

Joaquin Duato, Chief Executive Officer commented on the Q4 and 2021 results: ”Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honoured to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers.”

”Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond,” Duato added.

Johnson & Johnson chart (Monthly)

Share price trading higher following the latest results, up by around 2% during the trading day on Tuesday at $166.66 per share.

Johnson & Johnson is the 12th largest company in the world and with a total market cap of $438.19 billion.

You can trade Johnson & Johnson (JNJ) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: Johnson & Johnson, TradingView, GO Markets MT5, CompaniesMarketCap

Ready to start trading?

Disclaimer: Articles are from GO Markets analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by GO Markets. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.